SCHEDULE: Lincoln Alternative Strategies Discloses 9.9% Stake in XORTX

Lincoln Alternative Strategies LLC has reported a 9.9% beneficial ownership stake in XORTX Therapeutics Inc., holding 572,470 common shares.

Summary

• Lincoln Alternative Strategies LLC has acquired beneficial ownership of 572,470 common shares of XORTX Therapeutics Inc.
• This ownership represents 9.9% of the issuer's common stock outstanding as of October 23, 2025.
• The beneficial ownership percentage is based on 5,784,688 shares of XORTX Therapeutics Inc. common stock issued and outstanding.
• Lincoln Alternative Strategies LLC holds sole voting power and sole dispositive power over all 572,470 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of XORTX Therapeutics Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.9% stake by an institutional investor like Lincoln Alternative Strategies LLC can be viewed positively, as it suggests a belief in the company's value or potential. While not a direct endorsement of performance, it indicates substantial capital commitment.

Positives

• A significant institutional investor, Lincoln Alternative Strategies LLC, has taken a substantial 9.9% stake in XORTX Therapeutics Inc., potentially signaling confidence in the company's future prospects.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The emergence of a new significant institutional shareholder could be perceived positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a large shareholder may influence strategic decisions or communication.

Next Steps

• Lincoln Alternative Strategies LLC will be required to file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., increases or decreases by more than 1%).

Key Dates

Recommendation

While the disclosure of a significant institutional stake is generally a positive signal, a Schedule 13G filing alone does not provide enough fundamental information about XORTX Therapeutics Inc.'s operational performance, financial health, or strategic direction to warrant a 'buy' or 'sell' recommendation. It primarily indicates an investor's position. A 'hold' recommendation is appropriate until further financial and operational details are available for a comprehensive analysis.

Keywords

XORTX Therapeutics, Lincoln Alternative Strategies, Beneficial Ownership, Schedule 13G, Common Shares, Institutional Investment, Biotechnology, Pharmaceuticals